The promises and pitfalls of epigenetic therapies in solid tumours

European Journal of Cancer

Volumn 45, Issue 7, 2009, Pages 1129-1136

  Graham, Janet S ^a   Kaye, Stanley B ^b   Brown, Robert ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Biomarker; DNMTI; Epigenetics; HDAC inhibitor; Pharmacodynamic; Solid tumour

Indexed keywords

2 TRIFLUOROACETYLTHIOPHENE DERIVATIVE; 3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; CARBOPLATIN; CISPLATIN; DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; ROMIDEPSIN; THIOPHENE; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER THERAPY; CHEMOSENSITIZATION; CLINICAL TRIAL; DNA METHYLATION; DRUG ACTIVITY; EPIGENETICS; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; PHARMACODYNAMICS; PRIORITY JOURNAL; SEPSIS; SOLID TUMOR; T CELL LYMPHOMA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS AS TOPIC; DNA METHYLATION; DNA MODIFICATION METHYLASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS;

EID: 64049097640     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.01.003     Document Type: Article

References (43)

1. Sjoblom T., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314 5797 (2006) 268-274
2. Lyko F., and Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 97 20 (2005) 1498-1506
3. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 16 1 (2002) 6-21
4. Teodoridis J.M., Strathdee G., and Brown R. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist Update 7 4-5 (2004) 267-278
5. Santos F., et al. Dynamic reprogramming of DNA methylation in the early mouse embryo. Dev Biol 241 1 (2002) 172-182
6. Liu L., et al. Aging, cancer and nutrition: the DNA methylation connection. Mech Ageing Dev 124 10-12 (2003) 989-998
7. Richardson B. Impact of aging on DNA methylation. Ageing Res Rev 2 3 (2003) 245-261
8. Ahuja N., and Issa J.P. Aging, methylation and cancer. Histol Histopathol 15 3 (2000) 835-842
9. Issa J.P. CpG-island methylation in aging and cancer. Curr Top Microbiol Immunol 249 (2000) 101-118
10. Issa J.P. Aging, DNA methylation and cancer. Crit Rev Oncol Hematol 32 1 (1999) 31-43
11. Sorm F., et al. 5-Azacytidine, a new, highly effective cancerostatic. Experientia 20 4 (1964) 202-203
12. Santi D.V., Norment A., and Garrett C.E. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA 81 22 (1984) 6993-6997
13. Momparler R.L., Momparler L.F., and Samson J. Comparison of the antileukemic activity of 5-AZA-2′-deoxycytidine, 1-beta-d-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. Leuk Res 8 6 (1984) 1043-1049
14. Zhou L., et al. Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 321 4 (2002) 591-599
15. Cheng J.C., et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 95 5 (2003) 399-409
16. Holleran J.L., et al. Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clin Cancer Res 11 10 (2005) 3862-3868
17. Ting A.H., et al. CpG island hypermethylation is maintained in human colorectal cancer cells after RNAi-mediated depletion of DNMT1. Nat Genet 36 6 (2004) 582-584
18. Flynn J., et al. A potent cell-active allosteric inhibitor of murine DNA cytosine C5 methyltransferase. J Biol Chem 278 10 (2003) 8238-8243
19. Nieto M., et al. The absence of p53 is critical for the induction of apoptosis by 5-aza-2′-deoxycytidine. Oncogene 23 3 (2004) 735-743
20. Nakagawa H., et al. Generation of hydrogen peroxide primarily contributes to the induction of Fe(II)-dependent apoptosis in Jurkat cells by (-)-epigallocatechin gallate. Carcinogenesis 25 9 (2004) 1567-1574
21. Stresemann C., et al. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 66 5 (2006) 2794-2800
22. Schwartsmann G., et al. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest New Drug 18 1 (2000) 83-91
23. Kantarjian H.M., and Issa J.P. Decitabine dosing schedules. Semin Hematol 42 3 Suppl. 2 (2005) S17-S22
24. Issa J.P., et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103 5 (2004) 1635-1640
25. Plumb J.A., et al. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60 21 (2000) 6039-6044
26. Appleton K., et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 25 29 (2007) 4603-4609
27. Pohlmann P., et al. Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am J Clin Oncol 25 5 (2002) 496-501
28. Gaudet F., et al. Induction of tumors in mice by genomic hypomethylation. Science 300 5618 (2003) 489-492
29. Yang A.S., et al. Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in nice by genomic hypomethylation". Science 302 5648 (2003) 1153 author reply 1153
30. Yamada Y., et al. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc Natl Acad Sci USA 102 38 (2005) 13580-13585
31. Yoo C.B., et al. Delivery of 5-aza-2′-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res 67 13 (2007) 6400-6408
32. Fournel M., et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7 4 (2008) 759-768
33. Blumenschein Jr. G.R., et al. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drug 26 1 (2008) 81-87
34. Duvic M., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109 1 (2007) 31-39
35. Qian X., et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 5 8 (2006) 2086-2095
36. Kim M.S., et al. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63 21 (2003) 7291-7300
37. Munster P., et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 25 15 (2007) 1979-1985
38. Shao Y., et al. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 101 52 (2004) 18030-18035
39. Richon V.M. A new path to the cancer epigenome. Nat Biotechnol 26 6 (2008) 655-656
40. Agarwal R., and Kaye S.B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3 7 (2003) 502-516
41. Bibikova M., et al. Unraveling epigenetic regulation in embryonic stem cells. Cell Stem Cell 2 2 (2008) 123-134
42. Thibault A., Figg W.D., Bergan R.C., et al. A phase II study of 5-aza-2′-deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori 84 1 (1998) 87-89
43. Momparler R.L., Bouffard D.Y., Momparler L.F., et al. Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 8 4 (1997) 358-368